Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival …
Y Kawashima, T Fukuhara, H Saito… - The Lancet …, 2022 - thelancet.com
… The JO25567 study was a randomised, multicentre, phase 2 trial that compared
bevacizumab–erlotinib with erlotinib alone as first-line treatments in 154 Japanese patients with …
bevacizumab–erlotinib with erlotinib alone as first-line treatments in 154 Japanese patients with …
[HTML][HTML] Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan
R Morita, K Okishio, J Shimizu, H Saito, H Sakai… - Lung Cancer, 2020 - Elsevier
… Japanese patients with NSCLC who received nivolumab were analyzed retrospectively.
Patients who had started nivolumab treatment between April 2016 and December 2016 were …
Patients who had started nivolumab treatment between April 2016 and December 2016 were …
[HTML][HTML] Differences in molecular epidemiology of lung cancer among ethnicities (Asian vs. Caucasian)
M Izumi, T Suzumura, K Ogawa… - Journal of Thoracic …, 2020 - ncbi.nlm.nih.gov
… patients with lung adenocarcinoma, this research revealed KRAS mutations in 4.3% of
Japanese patients … less frequent in Japanese patients than in Caucasian patients, even among …
Japanese patients … less frequent in Japanese patients than in Caucasian patients, even among …
Clinical impacts of EGFR mutation status: analysis of 5780 surgically resected lung cancer cases
…, Japanese Joint Committee of Lung Cancer … - The Annals of thoracic …, 2021 - Elsevier
… 13,951 patients with nonsquamous non-small cell lung cancer included in this study, 5780
patients (… in a large cohort of Japanese patients with surgically treated lung adenocarcinoma …
patients (… in a large cohort of Japanese patients with surgically treated lung adenocarcinoma …
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised …
H Saji, M Okada, M Tsuboi, R Nakajima, K Suzuki… - The Lancet, 2022 - thelancet.com
… -stage lung cancer is only indicated for selected patients with … 90s in Japan, the early detection
of small-sized early lung … is a highly malignant disease, according to our results, patients …
of small-sized early lung … is a highly malignant disease, according to our results, patients …
Low-dose erlotinib treatment in elderly or frail patients with EGFR mutation–positive non–small cell lung cancer: A multicenter phase 2 trial
S Miyamoto, K Azuma, H Ishii, A Bessho… - JAMA …, 2020 - jamanetwork.com
… frail patients from 21 Japanese institutions after meeting the inclusion criteria.
Chemotherapy-naive patients withEGFR-activating mutation–positive non–small cell lung cancer …
Chemotherapy-naive patients withEGFR-activating mutation–positive non–small cell lung cancer …
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
K Nakagawa, T Hida, H Nokihara, M Morise, K Azuma… - Lung Cancer, 2020 - Elsevier
… The J-ALEX study compared the efficacy and safety of alectinib with crizotinib in Japanese
patients with advanced ALK-positive non-small-cell lung cancer (NSCLC). Superiority in …
patients with advanced ALK-positive non-small-cell lung cancer (NSCLC). Superiority in …
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
S Sugawara, M Kondo, T Yokoyama, T Kumagai… - International Journal of …, 2022 - Springer
… This study is the first prospective clinical trial in Japanese patients to evaluate brigatinib
efficacy and safety in patients with ALK-positive NSCLC who had not received ALK TKI treatment…
efficacy and safety in patients with ALK-positive NSCLC who had not received ALK TKI treatment…
… pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non–small cell lung cancer: a phase 3 …
I Okamoto, H Nokihara, S Nomura, S Niho… - JAMA …, 2020 - jamanetwork.com
… Our Japan-specific trial may limit the generalizability of the results, since all enrolled
participants are Japanese patients with NSCLC who usually show better survival than Western …
participants are Japanese patients with NSCLC who usually show better survival than Western …
A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer
…, H Asamura, West Japan Oncology Group… - The Journal of thoracic …, 2022 - Elsevier
… To select lung cancer that has no nodal involvement or lymphovascular invasion, the Japan
… The study defined radiologic noninvasive lung cancer as lung cancer 2 cm or less in size …
… The study defined radiologic noninvasive lung cancer as lung cancer 2 cm or less in size …
相关搜索
- survival data for patients lung cancer
- crizotinib in patients lung cancer
- older patients lung cancer
- cell lung cancer
- elderly patients lung cancer
- phase 3 trial lung cancer
- molecular epidemiology of lung cancer
- sublobar resection lung cancer
- egfr mutations lung cancer
- multicentre open label lung cancer
- multicentre phase cell lung cancer patients
- brigatinib in japanese patients
- weekly docetaxel lung cancer
- ground glass lung cancer
- small cell lung cancer patients